key: cord-0862529-n8by2jxl authors: Canacik, Omer; Sabirli, Ramazan; Altintas, Emel; Karsli, Emre; Karis, Denizhan; Kaymaz, Buse; Tukenmez Sabirli, Gizem; Kurt, Özgür; Koseler, Aylin title: Annexin A1 as a potential prognostic biomarker for COVID‐19 disease: Case–control study date: 2021-07-14 journal: Int J Clin Pract DOI: 10.1111/ijcp.14606 sha: 7819a8b457da66e59bc9065691504651fc00d4f8 doc_id: 862529 cord_uid: n8by2jxl BACKGROUND: Annexin A1 (AnxA1) is an important endogenous glucocoticoid protein that contributes to the suppression of inflammation by limiting the production of neutrophil and pro‐inflammatory cytokines. This study aims to determine the clinical predictivity value of blood AnxA1 levels in patients with mild and severe–critical pneumonia induced by COVID‐19. METHODS: This study employed a prospective, case–control study design and was conducted at Ankara Training and Research hospital between 10 February 2021 and 15 March 2021. A total of 74 patients (42 of whom had moderate and 32 of whom had severe/critical cases of COVID‐19 disease according to World Health Organization guidelines) and 50 nonsymptomatic healthy volunteers participated in the study. Blood samples were taken from patients at the time of hospital admission, after which serum was isolated. Following the isolation of serum, AnxA1 levels were evaluated using the enzyme‐linked immunosorbent assay method. RESULTS: The serum AnxA1 levels were measured as 25.5 (18.6‐38.6) ng/ml in the control group, 21.2 (14.7‐32) ng/ml in the moderate disease group, and 14.8 (9.7‐26.8) ng/ml in the severe/critical disease group. Serum AnxA1 levels were significantly lower in the severe/critical disease group compared with the control and moderate disease groups (P = .01 and P = .0001, respectively). Using receiver operating characteristic analysis, a larger area under the curve (AUC) for the serum AnxA1 levels of the control group (AUC = 0.715, 95% CI = 0.626‐0.803; P = .0001) was calculated compared with the COVID‐19 patient group for the diagnosis of COVID‐19 disease. The AnxA1 level was found to be 80% sensitive and 54.1% specific at a cut‐off level of 18.5 ng/ml for the diagnosis of COVID‐19 disease. Moreover, the AnxA1 level was found to be 69.8% sensitive and 58.1% specific at a cut‐off level of 17.2 ng/ml in predicting the need for intensive care unit (ICU) treatment. CONCLUSION: AnxA1 levels may be a beneficial biomarker in the diagnosis of COVID‐19 pneumonia and in predicting the need for ICU treatment in patients with COVID‐19 pneumonia at the time of admission to the emergency department. Coronavirus disease caused by the severe acute respiratory syndrome brought on by coronavirus 2 (SARS-CoV-2) was declared a global pandemic on 11 March 2020, and 157.2 million people had been infected and 3.2 million people had died worldwide by 6 May 2021. In the early days of May 2021, 800,000 new daily cases were confirmed, and 90,000 deaths were reported throughout the world. 1 COVID-19 infection can cause a wide clinical spectrum ranging from mild upper respiratory tract infections to sepsis and acute respiratory distress syndrome (ARDS). 2 Cytokine storm, which was firstly defined by Cron and Behrens. It occurs when excessive and disregulated cytokine production due to an uncontrolled immune response to different initiators (such as infections, malignancies, and rheumatologic diseases). COVID-19 can cause the production of cytokine storm inducing hyperinflammation, hyperactivation of the immune response, and multiple organ failure. [3] [4] [5] [6] Annexin A1 (AnxA1) is an important endogenous glucocoticoid protein that contributes to the suppression of inflammation in a variety of ways. Also known as lipocortin-1, it is one of the endogenous modulators of inflammation. AnxA1 is stored in high concentrations in the cytoplasm of neutrophils, macrophages, and monocytes in humans in states of no infection. 7 AnxA1 limits the production of neutrophil and pro-inflammatory cytokines. Moreover, AnxA1 induces neutrophil apoptosis, mediates monocyte recruitment, and augments the scavenging of apoptotic cells by macrophages. Recent research has revealed that AnxA1 also induces macrophage reprogramming for providing optimal homeostasis. 7 AnxA1 levels are induced both by inflammatory reponses and by exogenously ingested glucocorticoids. Exogenous glucocorticoids induce AnxA1 expression in monocytes and neutrophils, which play a crucial role in the anti-inflammatory responses. 8 Some studies on AnxA1 levels in sepsis patients have produced various results, such as in a study on patients with chronic obstructive pulmonary disease (COPD). AnxA1 levels were reported to decrease in sepsis patients, whereas another study found increased AnxA1 levels. 9,10 Serum AnxA1 levels were found to be higher in Stages 3 and 4 patients of Global Initiative for chronic obstructive lung disease (GOLD) COPD than patients with mild symptoms. 11 Another study found lower viral burden, higher mortality, and morbidity in ANXA1 −/− rats infected with influenza compared with wild-type rats. 12 In another study by Santana et al, low serum AnxA1 levels were found in patients infected with human T-lymphotropic virus (HTLV-1), and it was suggested that AnxA1 is an important marker on diagnosis and prognosis of HTLV-1-associated myelopathy/tropical spastic paraparesis. 13 As suggested by another study, the Ac2-26 mimetic peptide of AnxA1 could be an important treatment agent in severe COVID-19 disease. 14 However, to the authors' knowledge, there is no study based on the alterations of serum AnxA1 levels in patients with COVID-19 infection or value of AnxA1 for clinical prediction. We consider that blood AnxA1 levels may vary with clinical severity due to the significant increase in the inflammation cascade in patients with COVID-19 pneumonia. The present study aims to determine the clinical predictivity value of blood AnxA1 levels in patients with mild and severe/critical pneumonia induced by and to reveal the alterations of blood AnxA1 levels in patients with pneumonia compared with the control group. The present study is a prospective case-control study, and the re- The patient groups and the healthy control group were informed in detail about the study, and they were requested to complete the written consent forms before participating in the study. • Endogenous corticosteroids contribute to the suppression of inflammation in a variety of ways. • AnxA1 limits the production of neutrophil and proinflammatory cytokines. • The use of exogenous corticosteroids (especially dexamethasone) in severe/critical Coronavirus disease infections has also been recommended by World Health Organization guidelines for treating COVID-19 and has been put into clinical practice. • Serum Annexin A1 (AnxA1) levels were found to decrease in patients who had severe/critical cases of COVID-19 disease. The healthy control group included healthy volunteers with no history or diagnosis of any acute or chronic disease and infection and no known drug use. Patients whose diagnoses of COVID-19 infection were confirmed by positive RT-PCR in emergency department (ED) according to WHO guidelines and who gave their written consent were included in the study. 15 Subjects with no history of a known disease, no infectious symptoms, no drug use, and who provided written consent were included in the study. Patients who were diagnosed with heart, kidney, or liver failure, who had a history of acute pulmonary embolism, deep venous thrombosis, or chronic inflammatory disease, and who were pregnant were exclued from the study. The subjects included in the present study were clinically evaluated using WHO diagnosis and treatment guidelines for COVID-19. 15 The patient management algorithms were administered due to the updates of these guidelines. The patient groups were categorised as moderate disease and severe/critical disease according to WHO This group included subjects who had no history or diagnosis of any disease, no infection history within the last 2 weeks, no history of any particular medication, who were admitted to ED with complaints other than infectious issues, and who gave their written consent to participate in the study. Venous blood samples that were taken when the patients were admitted to ED were withdrawn into a dry test tube that did not contain anticoagulant and were then centrifugated for 10 minutes at 4000 rpm. Serum samples obtained from centrifugation were collected for laboratory analysis. Serum AnxA1 levels were analysed using a commercially available AnxA1 enzyme-linked immunosorbent assay (ELISA) Kit (Elabscience, E-EL-H5512, USA), per the manufacturer's protocol. Given that a similarly organised reference study did not exist, a power analysis was performed in line with the presumptions. The results revealed that at least 92 people (min. 46 for each cohort) were needed to achieve 95% power at a 90% confidence interval, assuming that the projected effect size would be high (f = 0.7). The SPSS package program was used for data analysis. The continuous variables were presented as median (interquartile range [IQR] ) and mean ± standard deviation. A Kolmogorov-Smirnov test was conducted to calculate the distribution type of the continuous variables. Mann-Whitney U or Kruskal-Wallis tests were used for analysing independent and nonparametric variables. Spearman correlation analysis was used to investigate correlation relationships between continous nonparametric variables. Receiver operating characteristic (ROC) curve analysis was used for the discriminant performance serum AnxA1 levels. The significance level was defined as P < .05 for all analyses. Symptom duration time was statistically higher in the severe/critical disease group than in the moderate disease group (7.5 ± 1.7 and 5.9 ± 1.1 days, respectively) (P = .02). As a result of the post hoc power analysis, the effect size of the AnxA1 concentrations for the differences between the two groups (patients and control) was moderate high (f = 0.66), and the power level observed for this effect size was 95%, and the reliability level was 93.96%. Serum AnxA1 levels were measured as 25.5 (18.6-38.6) ng/ml in the control group, 21.2 (14.7-32) ng/ml in the moderate disease group, and 14.8 (9.7-26.8) ng/ml in the severe/critical disease group. Serum AnxA1 levels were significantly lower in the severe/critical disease group compared with the control and moderate disease groups (P = .01 and P = .0001, respectively) (Table 1 and Figure 1 ). were matched by means of age and gender (P = .384 and P = .285, respectively) ( Table 2) . Vital findings and clinical data for the study groups are given in Table 2, and Table 3 presents the laboratory parameters of the subjects. When the correlation of AnxA1 with clinical and laboratory findings was analysed, a negative mild-moderate correlation was found between serum AnxA1 and CURB-65 score for the patients Furthermore, a larger AUC for the serum AnxA1 levels of patients who needed ICU treatment (AUC = 0.701, 95% CI = 0.582-0.819; P = .003) was calculated using ROC analysis. The AnxA1 level was found to be 69.8% sensitive and 58.1% specific at a cut-off level of 17.2 ng/ml for predicting the need for ICU treatment (Figure 3 ). The present study evaluated the clinical significance of serum AnxA1 level in COVID-19 pnemonia and concluded that the serum AnxA1 levels decreased as the clinical severity increased, and serum AnxA1 levels were 18.56 ng/ml in COVID-19 pnemonia with a sensitivity of 80% and specifity of 54%. Moreover, serum AnxA1 level may be considered as an indicator for predicting the need for ICU treatment even with its lower sensitivity and specifity. .0001* .044** .01*** .0001**** Abbreviations: IQR, interquartile range; SD, standard deviation. *P-value derived from Kruskal-Wallis test and refers to the comparison between all the groups.; **P-value is derived from Mann-Whitney U test and refers to the comparison between control and moderate disease groups.; ***P-value is derived from Mann-Whitney U test and refers to the comparison between control and severe/critical disease groups.; ****P-value is derived from Mann-Whitney U test and refers to the comparison between moderate disease group and severe/critical disease groups. Although the mechanism of glucocorticoid-induced leucine zipper (GILZ) protein, which is one of the proteins whose production is stimulated by exogenous glucocorticoids, has not been fully elucidated, it has been found to affect the functions of AnxA1. 8 AnxA1 mRNA expression is upregulated by glucocorticoids. 31 Studies have reported that inflammatory stimulation was much stronger and longer lasting in AnxA1 defective mice than wild-type mice. [32] [33] [34] In a study conducted by Tsai et al, AnxA1 levels and associated lipoxin were found to diminish in patients with sepsis, although no significant differences were found between survivor and nonsurvivor sepsis patients in terms of these markers. In addition, the study also found that pro-inflammatory cytokines increased and these markers decreased. 35 Among studies investigating the relationship between AnxA1 level and clinical prognosis in viral infections, a study by The present study has found that serum AnxA1 levels may be a ben- Moreover, the present study has pointed out that one of the response mechanisms to glucocorticoid therapy in patients with severe COVID-19 pneumonia using exogenous steroids may be through AnxA1. There is no funding statement for this study. The authors declare that they have no conflicts of interests. All the data (other than patient names) are available to share. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib Immunopathology of hyperinflammation in COVID-19 Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance Annexin A1 and glucocorticoids as effectors of the resolution of inflammation Plasma levels in sepsis patients of annexin A1, lipoxin A4, macrophage inflammatory protein-3a, and neutrophil gelatinase-associated lipocalin Serial changes in plasma annexin A1 and cortisol levels in sepsis patients Annexin A1 is elevated in patients with COPD and affects lung fibroblast function Annexins in influenza virus replication and pathogenesis Low Annexin A1 level in HTLV-1 infected patients is a potential biomarker for the clinical progression and diagnosis of HAM/TSP Ac2-26 mimetic peptide of annexin A1 to treat severe COVID-19: a hypothesis Clinical management of COVID-19: interim guidance (No. WHO/2019-nCoV/clinical/2020.5) Severity scoring in community-acquired pneumonia caused by Streptococcus pneumoniae: a 5-year experience Cochrane COVID-19 diagnostic test accuracy group. Routine laboratory testing to determine if a patient has COVID-19 Diagnostic value of peripheral hematologic markers for coronavirus disease 2019 (COVID-19): A multicenter, cross-sectional study Association between laboratory parameters and CT severity in patients infected with COVID-19: a retrospective, observational study Serum S100B protein as a marker of severity in COVID-19 patients D-Dimer as a potential biomarker for disease severity in COVID-19 Neutrophil to lymphocyte ratio, lymphocyte to monocyte ratio and platelet to lymphocyte ratio to predict the severity of COVID-19 Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis Laboratory parameters as predictors of mortality in COVID-19 patients on hospital admission Are serum interleukin 6 and surfactant protein D levels associated with the clinical course of COVID-19? Soluble P-selectin as a potential diagnostic and prognostic biomarker for COVID-19 disease: a casecontrol study Serum calprotectin as a novel biomarker for severity of COVID-19 disease Neutrophils: their role in innate and adaptive immunity Proresolving and tissue-protective actions of annexin A1-based cleavage-resistant peptides are mediated by formyl peptide receptor 2/lipoxin A4 receptor Design and characterization of a cleavage-resistant Annexin A1 mutant to control inflammation in the microvasculature Dexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogenactivated protein kinase Aberrant inflammation and resistance to glucocorticoids in annexin 1-/-mouse Modulation of inflammation and response to dexamethasone by Annexin 1 in antigen-induced arthritis Spatial and temporal profiles for anti-inflammatory gene expression in leukocytes during a resolving model of peritonitis Plasma levels in sepsis patients of annexin A1, lipoxin A4, macrophage inflammatory protein-3a, and neutrophil gelatinase-associated lipocalin Precision therapeutic targets for COVID-19 How to cite this article Annexin A1 as a potential prognostic biomarker for COVID-19 disease: Case-control study